Cover Image of Télécharger Lipid Manager  APK

4.9/5 - 12 voix

ID: org.acc.ldlmanager

Télécharger l'APK maintenant

La description de Lipid Manager


The ACC Lipid Manager app (formerly LDL-C Manager) provides 4-tools-in-1 to help clinicians manage a patient’s triglycerides and LDL-C from therapy initiation through treatment calibration with the goal of lowering ASCVD risk:
-ASCVD Risk Estimator: Calculate pretreatment ASCVD risk and determine the appropriateness of statin therapy for the patient
-LDL-C Lowering Therapy tool: Assess response to a statin, and determine if other therapies should be considered and in what order
-Statin Intolerance tool: Evaluate the patient for possible statin intolerance, and determine appropriate next steps
-Hypertriglyceridemia tool: Use the app to see tailored consensus recommendations for both lifestyle intervention and pharmacological management of high-risk patients with persistent hypertriglyceridemia
The information and recommendations in this App are not meant to represent the only or best course of care nor replace clinical judgement. Therapeutic options should be determined after discussion between the patient and their care provider.
— Statin Intolerance tool: Evaluate the patient for possible statin intolerance, and determine appropriate next steps
The information and recommendations in this App are not meant to represent the only or best course of care, or replace clinical judgment. Therapeutic options should be determined after discussion between the patient and their care provider.
Montre plus
  • Catégorie

    Médical
  • Mettez-le sur:

    Go Google Play org.acc.ldlmanager
  • Conditions:

    Android Varies with device+

Lipid Manager Varies with device APK pour Android Varies with device+

Version Varies with device pour Android Varies with device+
Mise à jour le 2023-02-05
Installe 10.000++
Taille du fichier 34.035.389 bytes
Autorisations voir les autorisations
Quoi de neuf This app has been updated in accordance with the 2022 ACC ECDP on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk to incorporate newer nonstatin agents, such as bempedoic acid, evinacumab, and inclisiran. This update also includes improved risk discrimination in patient evaluation, now incorporating CAC scoring, evidence of subclinical atherosclerosis, and Familial Hypercholesterolemia.

Historique des versions:

Montre plus
Appuyez sur APK
Montre plus